Prognostic Role of Tumor Microenvironment in DLBCL and Relation to Patients’ Clinical Outcome: A Clinical and Immunohistochemical Study

Table 3

The relation between macrophage marker CD68 and MMP9 expressions and the following parameters: age, gender, bulky diseases, B symptoms, anemia, LDH, performance status, extranodal involvement, bone marrow and CNS involvement, stage, IPI, Ki67, BCL2, relapse, overall survival, and therapy response.

	CD68		value	MMP9		value
	Low Ex	High Ex		Low Ex	High Ex
Age
0-59	26.2%	36.9%	0.321	26.2%	36.9%	0.753
+=60	20.0%	16.9%		13.8%	23.1%
Gender
Male	26.2%	30.8%	0.969	18.5%	38.5%	0.152
Female	20.0%	23.1%		21.5%	21.5%
Bulky dis
-ve	35.4%	46.2%	0.349	29.2%	52.3%	0.151
+ve	10.8%	7.7%		10.8%	7.7%
B symptoms
-ve	30.8%	43.1%	0.223	33.8%	40.0%	0.091
+ve	33.3%	20.0%		6.2%	20.0%
Anemia
-ve	29.2%	36.9%	0.656	24.6%	41.5%	0.521
+ve	16.9%	16.9%		15.4%	18.5%
LDH
Normal	3.1%	3.1%	0.633	1.5%	4.6%	0.472
High	43.1%	50.8%		38.5%	55.4%
Performance status
1	33.8%	44.6%	0.435	35.4%	43.1%	0.250
2	10.8%	9.2%		4.6%	15.4%
3	1.5%	0.0%		0.0%	1.5%
Extranodal involvement
0	29.2%	43.1%	0.085	29.2%	43.1%	0.808
1	15.4%	6.2%		9.2%	12.3%
2	1.5%	4.6%		1.5%	4.6%
Bone marrow and CNS involvement
-ve	38.5%	50.8%	0.155	35.4%	53.8%	0.587
+ve	7.7%	3.1%		4.6%	6.2%
Stage
1	6.2%	4.6%	0.870	6.2%	4.6%	0.463
2	4.6%	6.2%		6.2%	4.6%
3	20.0%	27.7%		18.5%	29.2%
4	15.4%	15.4%		9.2%	21.5%
IPI
1-2	26.2%	35.4%	0.455	27.7%	33.8%	0.298
3-4	20.0%	18.5%		12.3%	26.2%
Ki67
Low exp.	9.2%	9.2%	0.767	4.6%	13.8%	0.200
High exp.	36.9%	44.6%		35.4%	46.2%
BCl2
Low exp.	15.4%	15.4%	0.678	12.3%	18.5%	1.000
High exp.	30.8%	38.5%		27.7%	41.5%
Relapse
No	32.3%	36.9%	0.991	24.6%	44.6%	0.493
1-12 m	6.2%	7.7%		7.7%	6.2%
=+13 m	7.7%	9.2%		7.7%	9.2%
Overall survival
1-12 m	16.9%	13.8%	0.627	13.8%	16.9%	0.690
13-24 m	10.8%	13.8%		7.7%	16.9%
=+25	18.5%	26.2%		18.5%	26.2%
Therapy response
Regressive	10.8%	12.3%	0.975	7.7%	15.4%	0.202
Stationary	10.8%	13.8%		6.2%	18.5%
Progressive	24.6%	27.7%		26.2%	26.2%